This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Humana And Novo Nordisk Form Partnership To Improve Quality Outcomes For Patients Fighting Diabetes

Humana Inc. (NYSE: HUM) and Novo Nordisk Inc. (NYSE: NVO) today announced a one-year research partnership to explore diabetes treatment and care. Together, researchers will identify opportunities to change how patients might be treated to improve quality and outcomes for the millions of people who battle diabetes.

Humana, one of the nation’s largest health care companies, and Novo Nordisk, the world leader in diabetes care, will bring together researchers to study the treatment and progression of diabetes in the senior population. By leveraging both companies’ experience, this research will assist in the development of programs that will further enhance health and well-being of people with diabetes.

“This research collaboration is an important step in the fight against a disease that affects one out of every four Medicare members at Humana,” said William Fleming, Pharm.D, President of Humana Pharmacy Solutions. “We are excited about working together with Novo Nordisk as we will meaningfully advance care and improve the lives of our members.”

Humana, working through its research affiliate, Competitive Health Analytics, Inc., and Novo Nordisk are excited about the opportunity to partner together in the fight against diabetes.

“We look forward to collaborating with Humana on this project,” said Anne Phillips, M.D., Corporate Vice President, Clinical Development, Medical and Regulatory Affairs, Novo Nordisk Inc. “Health care quality is so important when it comes to achieving good outcomes, but we can’t measure it unless we have a strong partner with substantial data. It is our hope that this collaboration ultimately will create solutions that will improve outcomes for people with diabetes.”

According to the Centers for Disease Control and Prevention, nearly 26 million Americans have diabetes. This number is projected to significantly rise with an increasingly older, more sedentary and overweight population. Seven million of those with diabetes remain undiagnosed. Additionally, 79 million people in the United States have pre-diabetes, a condition in which individuals have blood glucose or A1c levels higher than normal but not high enough to be classified as diabetes. Diabetes is a leading cause of cardiovascular disease, strokes, blindness, kidney failure, and lower-limb amputations.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,031.14 +43.63 0.26%
S&P 500 1,984.13 -1.41 -0.07%
NASDAQ 4,518.9020 -48.6960 -1.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs